Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
Updated genomic screening tool for life-time breast cancer risk

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.17
Views: 2541
Rating:

Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake City, USA

Dr Jonathan Lancaster speaks with ecancer at SABCS 2017 about an updated genomic screening tool for life-time breast cancer risk.

He outlines how the test assesses 86 single nucleotide polymorphisms linked to cancer aetiology to provide clinically validated likelihood of disease.

Dr Lancaster considers the potential psychological impact for women with a family history of breast cancer, and notes that this tool is a modified function of existing myRisk assays, already in clinical use, so can be introduced to practice quickly and at no cost.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation